New Developments in the Synthesis of (E)-8-Styrylflavones

Orlando D. C. C. De Azevedo; Raquel S. G. R. Seixas; Artur M. S. Silva

doi:10.1055/s-0034-1380208

Synlett, Inhaltsverzeichnis

Synlett 2015; 26(10): 1379-1384
DOI: 10.1055/s-0034-1380208

letter

New Developments in the Synthesis of (E)-8-Styrylflavones

Autor*innen

Orlando D. C. C. De Azevedo

Department of Chemistry & QOPNA, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal eMail: raquel.grevy@ua.pt eMail: artur.silva@ua.pt
Raquel S. G. R. Seixas*

Department of Chemistry & QOPNA, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal eMail: raquel.grevy@ua.pt eMail: artur.silva@ua.pt
Artur M. S. Silva*

Department of Chemistry & QOPNA, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal eMail: raquel.grevy@ua.pt eMail: artur.silva@ua.pt

Abstract

Alle Artikel dieser Rubrik

Abstract

A novel route for the synthesis of new (E)-8-styrylflavones is reported. This methodology involves the regio- and stereoselective Heck cross-coupling reaction of 8-iodoflavones and styrene derivatives. The Heck precursors, 8-iodoflavones, were obtained through an efficient regioselective one-pot oxidative cyclization–iodination reaction of (E)-2′-hydroxychalcones by applying the iodine/dimethyl sulfoxide system.

Keywords

palladium - Heck reaction - styrylflavones - iodoflavones - cyclodehydrogenation

Volltext

Referenzen

References and Notes
1 Singh M, Kaur M, Silakari O. Eur. J. Med. Chem. 2014; 84: 206
2 lwashina T. J. Plant Res. 2000; 113: 287
3 Martens S, Mitho A. Phytochemistry 2005; 66: 2399
4 Kyle JA. M, Duthie GG In Flavonoids: Chemistry, Biochemistry and Applications . Andersen ØM, Markham KR. CRC Press; Boca Raton: 2006: 228

5a Ribeiro D, Freitas M, Tomé SM, Silva AM. S, Porto G, Fernandes E. Eur. J. Med. Chem. 2013; 67: 280
5b Shi Y, Wu D, Sun Z, Yang J, Chai H, Tang L, Guo Y. Phytother. Res. 2012; 26: 1410
5c Kilani-Jaziri S, Frachet V, Bhouri W, Ghedira K, Chekir-Ghedira L, Ronot X. Drug Chem. Toxicol. 2012; 35: 1
5d Lim H, Jin JH, Park H, Kim HP. Eur. J. Pharmacol. 2011; 670: 617
5e Casano G, Dumètre A, Pannecouque C, Hutter S, Azas N, Robin M. Bioorg. Med. Chem. 2010; 18: 6012
5f Roy S, Chatterjee P. Ind. Crops Prod. 2010; 32: 375
5g Mughal EU, Ayaz M, Hussain Z, Hasan A, Sadiq A, Riaz M, Malik A, Hussain S, Choudharyb MI. Bioorg. Med. Chem. 2006; 14: 4704
5h Wang C, Li H, Menga W, Qing F. Bioorg. Med. Chem. Lett. 2005; 15: 4456

6 Hyun J, Woo Y, Hwang D, Jo G, Eom S, Lee Y, Park JC, Lim Y. Bioorg. Med. Chem. Lett. 2010; 20: 5510

7a Cotelle N, Bernier J.-L, Catteau J.-P, Pommery J, Wallet J.-C, Gaydou EM. Free Radical Biol. Med. 1996; 20: 35
7b Kandaswami G, Perkins E, Soloniuk DS, Drzewiecki G, Middleton E. Anti-Cancer Drugs 1993; 4: 91

8a Todorova TZ, Traykov MG, Tadjer AV, Velkov ZhA. Comp. Theor. Chem. 2013; 1017: 85
8b Velkov ZhA, Kolev MK, Tadjer AV. Collect. Czech Chem. Commun. 2007; 72: 1461

9a Rasulev BF, Abdullaev ND, Syrov VN, Leszczynski J. QSAR Comb. Sci. 2005; 24: 1056
9b Hyun J, Woo Y, Hwang D, Jo G, Eom S, Lee Y, Park JC, Lim Y. Bioorg. Med. Chem. Lett. 2010; 20: 5510

For biological activities of 2-styrylchromones, see:

10a Shaw AY, Chang CY, Liau HH, Lu PJ, Chen HL, Yang CN, Li HY. Eur. J. Med. Chem. 2009; 44: 2552
10b Gomes A, Fernandes E, Silva AM. S, Pinto DC. G. A, Santos CM. M, Cavaleiro JA. S, Lima JL. F. C. Biochem. Pharmacol. 2009; 78: 171
10c Marinho J, Pedro M, Pinto DC. G. A, Silva AM. S, Cavaleiro JA. S, Sunkel CE, Nascimento MS. J. Biochem. Pharmacol. 2008; 75: 826
10d Gomes A, Fernandes E, Silva AM. S, Santos CM. M, Pinto DC. G. A, Cavaleiro JA. S, Lima JL. F. C. Bioorg. Med. Chem. 2007; 15: 6027
10e Conti C, Mastromarino P, Goldoni P, Portalone G, Desideri N. Antivir. Chem. Chemother. 2005; 16: 267
10f Momoi K, Sugita Y, Ishihara M, Satoh K, Kikuchi H, Hashimoto K, Yokoe I, Nishikawa H, Fujisawa S, Sakagami H. In Vivo 2005; 19: 157
10g Filipe P, Silva AM. S, Morliere P, Brito CM, Patterson LK, Hug GL, Silva JN, Cavaleiro JA. S, Maziere JC, Freitas JP, Santus R. Biochem. Pharmacol. 2004; 67: 2207
10h Desideri N, Mastromarino P, Conti C. Antivir. Chem. Chemother. 2003; 14: 195

For biological activities of 3-styrylchromones, see:

11a Shimada C, Uesawa Y, Ishii-Nozawa R, Ishihara M, Kagaya H, Kanamoto T, Terakubo S, Nakashima H, Takao K, Sugita Y, Sakagami H. Anticancer Res. 2014; 34: 5405
11b Takao K, Ishikawa R, Sugita Y. Chem. Pharm. Bull. 2014; 62: 810
11c Conti C, Desideri N. Bioorg. Med. Chem. 2010; 18: 6480
11d Sonawane SA, Chavan VP, Shingare MS, Karale BK. Indian J. Heterocycl. Chem. 2002; 12: 65

12 Dawood KM. Tetrahedron 2007; 63: 9642
13 Patonay T, Vasas A, Kiss-Szikszai A, Silva AM. S, Cavaleiro JA. S. Aust. J. Chem. 2010; 63: 1582
14 Vasas A, Patonay T, Kónya K, Silva AM. S, Cavaleiro JA. S. Aust. J. Chem. 2011; 64: 647
15 Fekete S, Patonay T, Silva AM. S, Cavaleiro JA. S. ARKIVOC 2012; (v): 210
16 Dahlén K, Grøtli M, Luthman K. Synlett 2006; 897
17 Rocha DH. A, Pinto DC. G. A, Silva AM. S, Patonay T, Cavaleiro JA. S. Synlett 2012; 23: 559
18 Rocha DH. A, Pinto DC. G. A, Silva AM. S. Synlett 2013; 24: 2683
19 Lokshin V, Heynderickx A, Samat A, Pèpe G, Guglielmetti R. Tetrahedron Lett. 1999; 40: 6761

20a Pinto DC. G. A, Silva AM. S, Cavaleiro JA. S. J. Heterocycl. Chem. 1996; 33: 1887
20b Pinto DC. G. A, Silva AM. S, Cavaleiro JA. S. Tetrahedron Lett. 1994; 35: 9459

21 Park H, Dao TT, Kim HP. Eur. J. Med. Chem. 2005; 40: 943
22 Ganguly NC, Chandra S, Barik SK. Synth. Commun. 2013; 43: 1351
23 Larsen L, Yoon DH, Weavers RT. Synth. Commun. 2009; 39: 2935
24 Dao TT, Kim SB, Sin K.-S, Kim S, Kim HP, Park H. Arch. Pharm. Res. 2004; 27: 278
25 Lu K, Chu J, Wang H, Fu X, Quan D, Ding H, Yao Q, Yu P. Tetrahedron Lett. 2013; 54: 6345
26 Zheng X, Meng W.-D, Xu Y.-Y, Cao J.-G, Qing F.-L. Bioorg. Med. Chem. Lett. 2003; 13: 881
27 Zembower DE, Zhang H. J. Org. Chem. 1998; 63: 9300
28 Zhou C, Dubrovsky AV, Larock RC. J. Org. Chem. 2006; 71: 1626

29a Likhar PR, Subhas MS, Roy M, Roy S, Kantam ML. Helv. Chim. Acta 2008; 91: 259
29b Zhang FJ, Li YL. Synthesis 1993; 565

30 Wang C.-L, Li H.-Q, Meng W.-D, Qing F.-L. Bioorg. Med. Chem. Lett. 2005; 15: 4456
31 Joo YH, Kim JK, Kang S.-H, Noh M.-S, Ha J.-Y, Choi JK, Lim KM, Lee CH, Chung S. Bioorg. Med. Chem. Lett. 2003; 13: 413
32 Khanna RN, Seshadri TR. Indian J. Chem. 1963; 1: 385
33 Optimized Experimental Procedure for the Synthesis of 2′-Hydroxy-4′,6′-dimethoxyacetophenone K₂CO₃ (7.23 g, 52.32 mmol) and Me₂SO₄ (2.48 mL, 26.16 mmol) were added to a solution of 2′,4′,6′-trihydroxyacetophenone (1, 2.00 g, 11.89 mmol) in acetone (50 mL). The reaction mixture was refluxed for 20 min under nitrogen atmosphere. After that, K₂CO₃ was filtered off, the acetone evaporated, and the residue recrystallized in EtOH affording the 2′-hydroxy-4′,6′-dimethoxyacetophenone in good yield (82%, 1.91 g).
34 Physical Data of (E)-2′-Hydroxy-3,4,4′,6′-tetramethoxychalcone (3b) Yellow needles; mp 156–157 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.84 and 3.92 (2 s, 2 × 3 H, 4′- and 6′-OCH₃), 3.94 (s, 3 H, 4-OCH₃), 3.95 (s, 3 H, 3-OCH₃), 5.98 (d, 1 H, J = 2.3 Hz, H-5′), 6.12 (d, 1 H, J = 2.3 Hz, H-3′), 6.90 (d, 1 H, J = 8.4 Hz, H-5), 7.13 (d, 1 H, J = 1.8 Hz, H-2), 7.22 (dd, 1 H, J = 1.8, 8.4 Hz, H-6), 7.78 (AB, 1 H, J = 15.6 Hz, H-β), 7.83 (AB, 1 H, J = 15.6 Hz, H-α), 14.41 (s, 2′-OH, 1 H) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 55.6, 55.8, 55.9, and 56.0 (3-, 4-, 4′-, and 6′-OCH₃), 91.3 (C-5′), 93.8 (C-3′), 106.3 (C-1′), 110.4 (C-2), 111.2 (C-5), 122.6 (C-6), 125.4 (C-α), 128.6 (C-1), 142.7 (C-β), 149.1 (C-3), 151.1 (C-4), 162.4 and 166.1 (C-4′ and C-6′), 168.4 (C-2′), 192.5 (C=O) ppm. ESI⁺-MS: m/z (%) = 345 (17) [M + H]⁺, 367 (100) [M + Na]⁺, 711 (5) [2M + Na]⁺. Anal. Calcd (%) for C₁₉H₂₀O₆: C, 66.27; H, 5.85. Found: C, 65.99; H, 5.77.
35 General Optimized Experimental Procedure for the Synthesis of (E)-2′-Hydroxychalcones 3a,b NaOH (aq, 60%, 37 mL) was added to a solution of 2′-hydroxy-4′,6′-dimethoxyacetophenone (1.50 g, 7.645 mmol) in MeOH (37 mL; in the case of derivative a), or in MeOH–DMSO (v/v, 37:4.5 mL; in the case of derivative b). After that, the appropriate benzaldehyde 2a,b (15.04 mmol) was added, and the reaction mixture was stirred for 3 h (derivative a) and 4 h (derivative b) at r.t. Then, the mixture was poured into ice (50 g) and H₂O (100 mL) and the pH adjusted to 4 with a solution of HCl (20%). After filtration, the precipitate was taken in CH₂Cl₂, washed repeatedly with a sat. solution of KHCO₃ (1 × 300 mL) and H₂O (3 × 300 mL), and the organic layer was dried over anhydrous Na₂SO₄. Subsequently, after solvent evaporation, the residue was recrystallized in EtOH giving the correspondent (E)-2′-hydroxychalcones 3a,b in good yields [3a (77%, 1.78 g); 3b (61%, 1.61 g)].
36 General Optimized Experimental Procedure for the Synthesis of 8-Iodoflavones 4a,b I₂ (0.100 g; 0.3181 mmol) was added to a solution of the appropriate (E)-2′-hydroxychalcone 3a,b (0.3181 mmol) in DMSO (1.0 mL), and the reaction mixture was refluxed for 45 min under N₂ atmosphere. After that, the reaction mixture was poured into ice (25 g), H₂O (50 mL), and Na₂S₂O₃·5H₂O (1 g). The obtained solid was filtered, taken in CH₂Cl₂ (100 mL), and washed with Na₂S₂O₃ (aq, 20%) (100 mL) and H₂O (3 × 100 mL). The organic layer was dried over anhydrous Na₂SO₄ concentrated and purified by flash column chromatography with a mixture of EtOAc–CH₂Cl₂(4:1) leading to 8-iodoflavones 4a,b in good yields [4a (77%, 107.3 mg); 4b (75%, 111.7 mg)].
37 Physical Data of α-Hydroxy-7-iodo-4,4′,6-trimethoxyaurone (5) White powder. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.83 (s, 3 H, 4′-OCH ₃), 4.03 and 4.06 (2 s, 2 × 3 H, 5-OCH₃ and 7-OCH₃), 6.18 (s, 1 H, H-5), 6.84 (d, 2 H, J = 8.9 Hz, H-3′,5′), 7.77 (d, 2 H, J = 8.9 Hz, H-2′,6′) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 55.6 (4′-OCH₃), 56.6 and 57.3 (4- and 6-OCH₃), 58.2 (C-7), 90.0 (C-5), 101.3 (C-2), 103.6 (C-3a), 114.4 (C-3′,5′), 124.3 (C-1′), 132.2 (C-2′,6′), 161.0 (C-4 or C-6), 165.0 (C-4′), 168.2 (C-4 or C-6), 172.2 (C-7a), 188.5 (C-α), 190.5 (C-3) ppm. ESI⁺-MS: m/z (%) = 493 (100) [M + K]⁺.
38 Physical Data of 3,8-Di-iodo-4′,5,7-trimethoxyflavone (6) White powder. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.90 (s, 3 H, 4′-OCH₃), 4.03 (s, 6 H, 5,7-OCH₃), 6.45 (s, 1 H, H-6), 7.03 (d, 2 H, J = 8.8 Hz, H-3′,5′), 8.02 (d, 2 H, J = 8.8 Hz, H-2′,6′) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 55.5 (4′-OCH₃), 56.6 and 56.8 (5- and 7-OCH₃), 63.9 (C-8), 89.2 (C-3), 92.0 (C-6), 106.2 (C-4a), 113.4 (C-3′,5′), 126.2 (C-1′), 132.0 (C-2′,6′), 157.6 (C-8a), 161.7 (C-2, C-5, C-7, or C-4′), 161.8 (C-2, C-5, C-7, or C-4′), 161.9 (C-2, C-5, C-7, or C-4′), 162.9 (C-5 or C-7), 172.7 (C-4) ppm. ESI⁺-MS: m/z (%) = 565 (94) [M + H]⁺, 587 (100) [M + Na]⁺.
39 Physical Data of 8-Iodo-3′,4′,5,7-tetramethoxyflavone (4b) Pale yellow powder; mp 273–275 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.97 (s, 3 H, 4′-OCH₃), 4.00 (s, 3 H, 3′-OCH₃), 4.04 (s, 6 H, 5- and 7-OCH₃), 6.44 (s, 1 H, H-6), 6.67 (s, 1 H, H-3), 6.99 (d, 1 H, J = 9.0 Hz, H-5′), 7.63–7.67 (m, 2 H, H-2′,6′) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 56.08 and 56.14 (3′- and 4′-OCH₃), 56.6 and 56.8 (5- and 7-OCH₃), 64.9 (C-8), 91.8 (C-6), 107.0 (C-3), 109.2 (C-2′), 109.9 (C-4a), 111.2 (C-5′), 119.9 (C-6′), 123.6 (C-1′), 149.2 (C-3′), 151.8 (C-4′), 157.5 (C-8a), 160.9 (C-2), 162.0 and 162.6 (C-5 and C-7), 177.5 (C-4) ppm. ESI⁺-MS: m/z (%) = 469 (100) [M + H]⁺, 491 (11) [M + Na]⁺, 959 (40) [2M + Na]⁺. Anal. Calcd (%) for C₁₉H₁₇IO₆: C, 48.74; H, 3.66. Found: C, 48.90; H, 3.64.
40 Physical Data of (E)-8-[2-(4-Methoxyphenyl)vinyl]-4′,5,7-trimethoxyflavone (8a) Pale yellow powder; mp 224–225 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.86 (s, 3 H, 4′′-OCH₃), 3.88 (s, 3 H, 4′-OCH₃), 4.03 (s, 3 H, 5-OCH₃), 4.04 (s, 3 H, 7-OCH₃), 6.46 (s, 1 H, H-6), 6.62 (s, 1 H, H-3), 6.93 (d, 2 H, J = 8.7 Hz, H-3′′,5′′), 6.98 (d, 2 H, J = 8.8 Hz, H-3′,5′), 7.30 (d, 1 H, J = 16.6 Hz, H-α), 7.45 (d, 1 H, J = 16.6 Hz, H-β), 7.48 (d, 2 H, J = 8.7 Hz, H-2′′,6′′), 7.86 (d, 2 H, J = 8.8 Hz, H-2′,6′) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 55.4 and 55.5 (4′- and 4′′-OCH₃), 56.0 and 56.4 (5- and 7-OCH₃), 91.6 (C-6), 107.4 (C-3), 108.0 (C-8), 109.1 (C-4a), 114.2 (C-3′′,5′′), 114.5 (C-3′,5′), 115.7 (C-α), 124.2 (C-1′), 127.4 (C-2′′,6′′), 127.9 (C-2′,6′), 131.3 (C-1′′), 132.4 (C-β), 156.2 (C-8a), 159.2 (C-4′′), 159.7 (C-5), 161.0 (C-2), 161.2 (C-7), 162.0 (C-4′), 178.2 (C-4) ppm. ESI⁺-MS: m/z (%) = 445 (100) [M + H]⁺, 467 (11) [M + Na]⁺, 911 (60) [2M + Na]⁺. EI⁺-HRMS: m/z calcd for [C₂₇H₂₄O₆]: 444.1573; found: 444.1572.
41 General Optimized Experimental Procedure for the Synthesis of (E)-8-Styrylflavones 8a–c The appropriate styrene 7a,b (0.45 mmol) was added to a mixture of the appropriate 8-iodoflavone 4a,b (0.09 mmol), KCl (0.09 mmol), TBAB (0.14 mmol), K₂CO₃ (0.14 mmol), and PdCl₂ (5.4 µmol) in NMP (1.5 mL). Each reaction mixture was heated to 100 °C for 24 h under N₂ atmosphere. After this time, the mixture was poured into H₂O (100 mL) and the pH was adjusted to 5 by adding dropwise a solution of HCl (50%). Afterwards, the obtained residue was extracted with CH₂Cl₂ (100 mL), washed with H₂O (4 × 200 mL) and the organic layer dried over anhydrous Na₂SO₄. To remove any traces of NMP, the residue was dissolved in toluene and evaporated to dryness. Purification by TLC [two mixtures were used as eluent: first CH₂Cl₂–MeOH (9:1) and then CH₂Cl₂–acetone (4:1)] with subsequent recrystallization in EtOH lead to (E)-8-styrylflavones 8a–c in good yields [8a (87%, 34.8 mg); 8b (90%, 38.4 mg); 8c (93%, 42.2 mg)].
42 Physical Data of 8-[1-(4-Methoxyphenyl)vinyl]-4′,5,7-trimethoxyflavone (9a) Pale yellow powder; mp 151–152 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.78, 3.82, 3.88, and 4.05 (4 s, 4 × 3 H, 4′-, 4′′′-, 5-, and 7-OCH₃), 5.25 (d, 1 H, J = 0.7 Hz, H-2′′_a), 6.02 (d, 1 H, J = 0.7 Hz, H-2′′_b), 6.50 (s, 1 H, H-6), 6.55 (s, 1 H, H-3), 6.83 (d, 2 H, J = 8.8 Hz, H-3′,5′ or H-3′′′,5′′′), 6.84 (d, 2 H, J = 8.9 Hz, H-3′,5′or H-3′′′,5′′′), 7.32 (d, 2 H, J = 8.8 Hz, H-2′′′,6′′′), 7.46 (d, 2 H, J = 8.9 Hz, H-2′,6′) ppm. ESI⁺-MS: m/z (%) = 445 (100) [M + H]⁺, 467 (32) [M + Na]⁺, 911 (19) [2M + Na]⁺. ESI⁺-HRMS: m/z calcd for [C₂₇H₂₄O₆ + H⁺] 445.1646; found: 445.1639.
43 Physical Data of 4′,5,7-Trimethoxyflavone (10) White powder; mp 154–156 °C. ¹H NMR (300.13 MHz, CDCl₃): δ = 3.88 (s, 3 H, 4′-OCH₃), 3.91 (s, 3 H, 7-OCH₃), 3.96 (s, 3 H, 5-OCH₃), 6.37 (d, 1 H, J = 2.2 Hz, H-6), 6.56 (d, 1 H, J = 2.2 Hz, H-8), 6.60 (s, 1 H, H-3), 7.00 (d, 2 H, J = 8.8 Hz, H-3′,5′), 7.83 (d, 2 H, J = 8.8 Hz, H-2′,6′) ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ = 55.5 (4′-OCH₃), 55.8 (7-OCH₃), 56.5 (5-OCH₃), 92.8 (C-8), 96.1 (C-6), 107.7 (C-3), 109.2 (C-4a), 114.4 (C-3′,5′), 123.9 (C-1′), 127.6 (C-2′,6′), 159.9 (C-8a), 160.1 (C-2), 160.9 (C-5), 162.0 (C-4′), 163.9 (C-7), 177.7 (C-4) ppm. ESI⁺-MS: m/z (%) = 313 (43) [M + H]⁺, 335 (27) [M + Na]⁺, 647 (100) [2M + Na]⁺.